Heron Therapeutics (NASDAQ:HRTX) Share Price Crosses Above 200 Day Moving Average - What's Next?

Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Get Free Report) crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $1.94 and traded as high as $2.22. Heron Therapeutics shares last traded at $2.07, with a volume of 1,459,150 shares traded.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. HC Wainwright assumed coverage on Heron Therapeutics in a research report on Monday, June 9th. They set a "buy" rating and a $6.00 price objective on the stock. Wall Street Zen raised Heron Therapeutics from a "hold" rating to a "buy" rating in a report on Friday, June 6th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $4.00 target price on shares of Heron Therapeutics in a report on Friday, April 11th.

Heron Therapeutics Stock Performance

The business has a 50 day moving average of $2.06 and a two-hundred day moving average of $1.95. The firm has a market capitalization of $330.29 million, a price-to-earnings ratio of -36.08 and a beta of 1.18.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported $0.01 earnings per share for the quarter, topping analysts' consensus estimates of ($0.01) by $0.02. The firm had revenue of $38.90 million for the quarter, compared to analyst estimates of $37.08 million. On average, equities analysts predict that Heron Therapeutics, Inc. will post -0.13 EPS for the current fiscal year.

Hedge Funds Weigh In On Heron Therapeutics

Institutional investors have recently bought and sold shares of the company. Nicolet Advisory Services LLC purchased a new stake in shares of Heron Therapeutics in the fourth quarter worth $25,000. RFP Financial Group LLC purchased a new stake in shares of Heron Therapeutics during the first quarter worth about $26,000. Argent Advisors Inc. purchased a new stake in shares of Heron Therapeutics during the fourth quarter worth about $31,000. Focus Partners Wealth purchased a new stake in Heron Therapeutics in the fourth quarter worth about $31,000. Finally, Valeo Financial Advisors LLC lifted its holdings in Heron Therapeutics by 34.1% in the first quarter. Valeo Financial Advisors LLC now owns 18,152 shares of the biotechnology company's stock worth $40,000 after buying an additional 4,619 shares during the period. Hedge funds and other institutional investors own 80.01% of the company's stock.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.